News | Radiopharmaceuticals and Tracers | May 22, 2017

Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18

Companies also announce the extension and expansion of their existing commercial supply agreement for nuclear products through 2020

Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18

May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a definitive license agreement  for the continued Phase III development and worldwide commercialization of flurpiridaz F-18. Flurpiridaz F-18 is an investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent that may improve the diagnosis of coronary artery disease (CAD), the most common form of heart disease. The definitive agreement follows the signing of a term sheet previously announced in late February 2017.

Under the definitive agreement, GE Healthcare will lead and fund the development program of flurpiridaz F-18, including the second Phase III clinical study. GE Healthcare will also have exclusive worldwide rights for the commercialization of flurpiridaz F-18. Lantheus will collaborate in both the development and commercialization process through a joint steering committee. Lantheus also maintains the option to co-promote the imaging agent in the United States.

Lantheus will receive a $5 million upfront cash payment and, if successful, up to $60 million in regulatory and sales milestones payments, plus double-digit royalties on U.S. sales and single-digit royalties on sales outside of the U.S.

Separately, the companies have also extended and expanded their current commercial agreement under which Lantheus will continue to supply GE Healthcare with TechneLite (Technetium Tc99m Generators), Gallium-67 (Gallium Citrate Ga 67 Injection) and Xenon-133 (Xenon Xe 133 Gas) through Dec. 31, 2020.

For more information: www.gehealthcare.com, www.lantheus.com

Related Content

News | Cardiac Imaging

June 24, 2022 — The Radiological Society of North America (RSNA) reports that Coronary Artery Calcium (CAC) scoring with ...

Home June 24, 2022
Home
News | Cardiac Imaging

June 23, 2022 — New research from the Smidt Heart Institute at Cedars-Sinai shows for the first time that the path ...

Home June 23, 2022
Home
News | Cardiac Imaging

May 2, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), routine visual ordinal coronary artery calcium ...

Home May 02, 2022
Home
News | Cardiac Imaging

April 11, 2022 — Radiation to the heart during treatment for locally advanced lung cancer is associated with an ...

Home April 11, 2022
Home
News | Cardiac Imaging
February 21, 2022 – Acute coronary syndromes (such as heart attacks) and strokes are a leading cause of morbidity and ...
Home February 21, 2022
Home
News | Cardiac Imaging
February 21, 2022 – Researchers at Michigan Medicine have found a novel method of measuring growth in the body’s largest ...
Home February 21, 2022
Home
News | Cardiac Imaging

February 18, 2022 — GE Healthcare has announced that it has received approval from the European Medicines Agency (EMA) ...

Home February 18, 2022
Home
Videos | Cardiac Imaging

Interview with Campbell Rogers, M.D., chief medical officer of HeartFlow which has developed a CT image-based fractional ...

Home February 01, 2022
Home
Videos | Cardiac Imaging

American Society of Nuclear Cardiology (ASNC) President Dennis Calnon, M.D., MASNC, FASE, FSCCT, director of cardiac ...

Home February 01, 2022
Home
Subscribe Now